Veru (VERU) to Release Earnings on Thursday

Veru (NASDAQ:VERU - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Thursday, February 13th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $3.02 million for the quarter. Investors that wish to register for the company's conference call can do so using this link.

Veru (NASDAQ:VERU - Get Free Report) last released its earnings results on Monday, December 16th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. Veru had a negative return on equity of 92.88% and a negative net margin of 223.85%. On average, analysts expect Veru to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Veru Price Performance

VERU traded down $0.03 on Friday, reaching $0.56. 3,157,988 shares of the stock were exchanged, compared to its average volume of 5,537,147. The company's 50-day moving average price is $0.73 and its 200 day moving average price is $0.78. The firm has a market capitalization of $81.30 million, a PE ratio of -1.98 and a beta of -0.54. Veru has a fifty-two week low of $0.36 and a fifty-two week high of $1.92.

Remove Ads

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. HC Wainwright reaffirmed a "buy" rating and set a $3.00 target price on shares of Veru in a report on Thursday, January 2nd. Oppenheimer restated an "outperform" rating and set a $5.00 price objective on shares of Veru in a research note on Tuesday, November 5th.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.